AU9343098A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
AU9343098A
AU9343098A AU93430/98A AU9343098A AU9343098A AU 9343098 A AU9343098 A AU 9343098A AU 93430/98 A AU93430/98 A AU 93430/98A AU 9343098 A AU9343098 A AU 9343098A AU 9343098 A AU9343098 A AU 9343098A
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU93430/98A
Inventor
Alan Frank Parr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU9343098A publication Critical patent/AU9343098A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
AU93430/98A 1997-08-19 1998-08-17 Pharmaceutical composition Abandoned AU9343098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9717428.8A GB9717428D0 (en) 1997-08-19 1997-08-19 Pharmaceutical composition
GB9717428 1997-08-19
PCT/EP1998/005194 WO1999008666A2 (en) 1997-08-19 1998-08-17 Pharmaceutical composition comprising an azateroid

Publications (1)

Publication Number Publication Date
AU9343098A true AU9343098A (en) 1999-03-08

Family

ID=10817619

Family Applications (1)

Application Number Title Priority Date Filing Date
AU93430/98A Abandoned AU9343098A (en) 1997-08-19 1998-08-17 Pharmaceutical composition

Country Status (15)

Country Link
EP (1) EP1007010A2 (en)
JP (1) JP2002511101A (en)
KR (1) KR20010014080A (en)
CN (1) CN1263461A (en)
AR (1) AR016629A1 (en)
AU (1) AU9343098A (en)
BR (1) BR9810458A (en)
CA (1) CA2295016A1 (en)
CO (1) CO4960657A1 (en)
GB (1) GB9717428D0 (en)
MA (1) MA26531A1 (en)
PE (1) PE105699A1 (en)
TR (1) TR199903209T2 (en)
WO (1) WO1999008666A2 (en)
ZA (1) ZA987392B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6633A (en) * 2002-11-22 2004-05-23 Omega Farma Ehf. Compositions of finasteride tablets
JP4880461B2 (en) 2003-08-13 2012-02-22 バイオコン・リミテッド Microparticulate fatty acid salt solid formulation for therapeutics
JP2007517788A (en) * 2004-01-02 2007-07-05 ファルマコン・フォルシュング・ウント・ベラートゥング・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Process for producing 1,2-unsaturated azasteroids
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
ES2385240B1 (en) 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
CN103169712B (en) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 Improve dutasteride's preparation of bioavilability and preparation method thereof
WO2014002015A1 (en) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition comprising dutasteride
ES2555485T1 (en) 2014-05-26 2016-01-04 Galenicum Health S.L. Pharmaceutical compositions containing an active agent
KR101679992B1 (en) 2015-12-31 2016-11-28 주식회사 유유제약 Pharmaceutical composition comprising dutasteride and propylene glycol monolaurate and preparation method of the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
DE3607651A1 (en) * 1986-03-06 1987-09-10 Schering Ag COMBINATION OF AROMATASE INHIBITORS AND TESTOSTERONE-5 (ALPHA) REDUCTASE INHIBITORS
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss

Also Published As

Publication number Publication date
MA26531A1 (en) 2004-12-20
WO1999008666A3 (en) 1999-04-15
EP1007010A2 (en) 2000-06-14
KR20010014080A (en) 2001-02-26
JP2002511101A (en) 2002-04-09
GB9717428D0 (en) 1997-10-22
ZA987392B (en) 2000-02-17
PE105699A1 (en) 1999-11-25
TR199903209T2 (en) 2000-05-22
CA2295016A1 (en) 1999-02-25
CN1263461A (en) 2000-08-16
CO4960657A1 (en) 2000-09-25
WO1999008666A2 (en) 1999-02-25
AR016629A1 (en) 2001-07-25
BR9810458A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
AU6740298A (en) Pharmaceutical composition
AU4762797A (en) Pharmaceutical compositions
AU2967597A (en) Pharmaceutical compositions
AU5387898A (en) Pharmaceutical agents
AU8107998A (en) Pharmaceutical compositions
AU3777897A (en) Pharmaceutical compositions
AU5335798A (en) Stomatic composition
AU5317598A (en) Novel pharmaceutical compositions
AU8591898A (en) Pharmaceutical compounds
AU8747498A (en) Food-preservative composition
AU7904998A (en) Pharmaceutical composition containing peptichemio
GB9717444D0 (en) Pharmaceutical composition
AU2531295A (en) Pharmaceutical composition
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
AU9343098A (en) Pharmaceutical composition
AU8121998A (en) Composition
AUPP332898A0 (en) Pharmaceutical composition
AU1098499A (en) Emulsifier-lipid composition
AU4326197A (en) Pharmaceutical compositions
AUPN862596A0 (en) Pharmaceutical compositions
AU4457597A (en) Pharmaceutical compositions
GB9717770D0 (en) Pharmaceutical composition
GB2321190B (en) Pharmaceutical composition
GB9726781D0 (en) Pharmaceutical composition
AUPO590197A0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination